Genentech Was Too Slow In Trying To Halt Amgen's Herceptin Biosimilar Launch

Genentech's delay in requesting an injunction, as well as its licensing deals with Mylan, Celltrion and Pfizer, show it won't suffer irreparable harm from sales of Amgen's biosimilar, judge says.